A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...
CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy ...
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of drugs for schizophrenia in more than 30 years.
Bristol Myers Squibb has received U.S. FDA approval for a new schizophrenia drug, marking the first new antipsychotic medication in decades. The drug, Cobenfy, lacks warnings about increased mortality ...
The Dow Jones Industrial Average reached a record high following a modest inflation report, spurring hopes for additional ...
The blue-chip Dow Jones Industrial Average closed at a record high today as investors welcomed a subdued inflation report ...
The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...
British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the ...
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in decades.
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback